“This 2020, BioNTech will prove the skeptics wrong.” At the beginning of January, in front of investors gathered in San Francisco, Ughur Shahin tells the truth. But not for all the right reasons… Twelve years ago, the immunologist founded the company BioNTech with his partner Ozlem Turecchi to develop messenger RNA-based immunotherapy. Only a few of its researchers work on infectious diseases, and a partnership with Pfizer is outlined against influenza. When he faces American investors, therefore, Shahin is thinking about the cancer against which BioNTech is about to launch seven clinical trials. But neither cancer nor personalized medicine will be BioNTech’s glory. two weeks after this American tour, the company will make a decisive choice that will lead it to change the face of the global epidemic.
One weekend at the end of January 2020, in the family’s small apartment in Mainz, Germany, Shahin reads an article…
Source: Le Figaro
